
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Therapy: Preclinical |
Authors' Affiliations: 1 Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, Georgia and 2 Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland
Requests for reprints: Kebin Liu, Department of Biochemistry and Molecular Biology, Medical College of Georgia, 1459 Laney Walker Boulevard, Augusta, GA 30912. Phone: 706-721-9483; Fax: 706-721-6608; E-mail: Kliu{at}mcg.edu.
Purpose: One of the impediments of immunotherapy against cancer is the suppression of tumor-specific CTLs in the tumor microenvironment, partly due to the selective inhibition of the perforin pathway and the emergence of Fas-resistant tumors. Therefore, we sought to identify perforin- and Fas-independent cytotoxic pathways and explored the potential of targeting LTßR with tumor-specific CTLs to induce tumor rejection in vivo.
Experimental Design: Fas-resistant tumors were examined for their susceptibility to perforin-deficient (pfp) CTLs via CTL adoptive transfer in mouse models of experimental lung metastasis. The specificity of LTßR, a cell surface death receptor, in causing tumor rejection by CTLs was analyzed by LTßR-specific neutralizing monoclonal antibody in vitro. The specificity and efficacy of LTßR in the suppression of established tumors was further investigated by silencing LTßR in tumor cells in vivo.
Results: pfp CTLs exhibited significant cytotoxicity against Fas-resistant tumors in vivo. The perforin- and Fas-independent cytotoxicity was directly mediated, at least in part, by the adoptively transferred CTLs. It was observed that LTßR was expressed on the tumor cell surface, and LT
, LTß, and LIGHT, all of which are ligands for LTßR, were either constitutively expressed or activated in the tumor-specific CTLs and primary CD8+ T cells. Blocking LTßR with LTßR-specific neutralizing monoclonal antibody decreased CTL cytotoxicity in vitro. Silencing LTßR using LTßR-specific short hairpin RNA reduced the ability of pfp CTLs to induce tumor rejection in vivo.
Conclusion: LTßR directly mediates CTL-directed tumor rejection in vivo. Targeting LTßR with tumor-specific CTLs is a potential therapeutic approach.
This article has been cited by other articles:
![]() |
D. Yang, S. Wang, C. Brooks, Z. Dong, P. V. Schoenlein, V. Kumar, X. Ouyang, H. Xiong, G. Lahat, A. Hayes-Jordan, et al. IFN Regulatory Factor 8 Sensitizes Soft Tissue Sarcoma Cells to Death Receptor-Initiated Apoptosis via Repression of FLICE-like Protein Expression Cancer Res., February 1, 2009; 69(3): 1080 - 1088. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. McGough, D. Yang, S. Huang, D. Georgi, S. M. Hewitt, C. Rocken, M. Tanzer, M. P.A. Ebert, and K. Liu DNA Methylation Represses IFN-{gamma}-Induced and Signal Transducer and Activator of Transcription 1-Mediated IFN Regulatory Factor 8 Activation in Colon Carcinoma Cells Mol. Cancer Res., December 1, 2008; 6(12): 1841 - 1851. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |